Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, gel-e’s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.
Total Funding: $10,600,000
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2007
Aug 2021
- Medcura Raised $7.4M From Private Equity
Jul 2021
- Medcura Launched Antibacterial Hemostatic Gel
Apr 2021
- Medcura Publishes Successful Results From Clinical Study
Feb 2021
- Medcura Expanded Internal Hemostat Program
